TOKYO, Oct. 14, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that VEOZAH™ (fezolinetant), its first-in-class, targeted, non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, will be...
Hence then, the article about astellas to present first real world veozah fezolinetant data at 2025 annual meeting of the menopause society was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society )
Also on site :
- Amazon’s 'Incredibly Soft' Lettuce-Trim Lounge Set Feels Like a Designer Brand That’s 8 Times the Price
- GPGI, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GPGI
- Quote of the Day: Big Little Feelings Founders Share the Parenting Lesson That Can Change How Kids See the World